Literature DB >> 7966621

DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors.

I E Alexander1, D W Russell, A D Miller.   

Abstract

None of the vector systems currently available for gene therapy applications have been shown to be capable of both efficient gene transfer into nondividing cells and long-term expression through stable integration into host cell DNA. While integrating vectors based on adeno-associated virus are capable of mediating gene transfer into nondividing cells, this process is 200-fold less efficient than transduction of dividing cells. We demonstrate that the transduction efficiency of adeno-associated virus vectors can be increased by treatment with DNA-damaging agents. Nondividing cells are especially responsive, with increases in transduction efficiency of up to 750-fold. This finding has the potential to facilitate gene therapy applications requiring gene transfer to nondividing cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966621      PMCID: PMC237296          DOI: 10.1128/JVI.68.12.8282-8287.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  Use of adeno-associated virus as a general transduction vector for mammalian cells.

Authors:  N Muzyczka
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice.

Authors:  G Friedrich; P Soriano
Journal:  Genes Dev       Date:  1991-09       Impact factor: 11.361

3.  A recombinant retrovirus encoding alkaline phosphatase confirms clonal boundary assignment in lineage analysis of murine retina.

Authors:  S C Fields-Berry; A L Halliday; C L Cepko
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

4.  Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors.

Authors:  J Limon; P Dal Cin; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1986-12

5.  Cloning, sequencing, and chromosomal localization of human term placental alkaline phosphatase cDNA.

Authors:  W Kam; E Clauser; Y S Kim; Y W Kan; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus.

Authors:  J R Schlehofer; M Ehrbar; H zur Hausen
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

7.  Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase.

Authors:  A I Geller; A Freese
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

8.  An Escherichia coli recBCsbcBrecF host permits the deletion-resistant propagation of plasmid clones containing the 5'-terminal palindrome of minute virus of mice.

Authors:  R Boissy; C R Astell
Journal:  Gene       Date:  1985       Impact factor: 3.688

9.  Expression of active, membrane-bound human placental alkaline phosphatase by transfected simian cells.

Authors:  J Berger; A D Howard; L Gerber; B R Cullen; S Udenfriend
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

10.  DNA amplification of adeno-associated virus as a response to cellular genotoxic stress.

Authors:  A O Yalkinoglu; R Heilbronn; A Bürkle; J R Schlehofer; H zur Hausen
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

View more
  61 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

3.  E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein.

Authors:  Joseph S Orlando; David A Ornelles
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome.

Authors:  L Zentilin; A Marcello; M Giacca
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

Authors:  C L Halbert; T A Standaert; M L Aitken; I E Alexander; D W Russell; A D Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 6.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

7.  Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes.

Authors:  Marcela P Cataldi; Douglas M McCarty
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

8.  Overexpression of cyclin A inhibits augmentation of recombinant adeno-associated virus transduction by the adenovirus E4orf6 protein.

Authors:  M Grifman; N N Chen; G P Gao; T Cathomen; J M Wilson; M D Weitzman
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Adeno-associated virus vector integration junctions.

Authors:  E A Rutledge; D W Russell
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

10.  In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.

Authors:  Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.